SCHEMBL951235

SCHEMBL951235

CCn1c2ccc(S(=O)(=O)O)cc2c(=O)c2cc3c(cc21)c(=O)c1cc(S(=O)(=O)O)ccc1n3CCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
PTGER4 P35408 1/20 0.35
PARG Q86W56 2/20 0.34
SIRT2 Q8IXJ6 2/20 0.34
SIRT1 Q96EB6 1/20 0.34
APEX1 P27695 1/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
PSEN1 P49768 2/20 0.32
PSEN2 P49810 2/20 0.32
APH1B Q8WW43 2/20 0.32
NCSTN Q92542 2/20 0.32
APH1A Q96BI3 2/20 0.32
PSENEN Q9NZ42 2/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14266803 0.91 KDM4E (0.31) MEN1KMT2AKDM4EUSP2PTGER4
SCHEMBL357128 0.89 HDAC1 (0.41) SMN1; SMN2MAPTCNR2
SCHEMBL1415560 0.88 TERT (0.32) MEN1KMT2AAPEX1MAPTALDH1A1
SCHEMBL4581975 0.87 PTGDR2 (0.38) MEN1KMT2AKDM4EUSP2PTGER4
SCHEMBL1401219 0.83 FABP4 (0.45) KDM4EPTGER4APEX1HPGDPSEN1
SCHEMBL14266801 0.80
SCHEMBL13036113 0.80 SIRT2 (0.35) MEN1KMT2AKDM4EUSP2PTGER4
SCHEMBL354525 0.78 HSD17B10 (0.40) SMN1; SMN2CNR2ALDH1A1LMNA
SCHEMBL353790 0.76 HDAC1 (0.51) SMN1; SMN2MAPT
SCHEMBL1416000 0.76 PSEN1 (0.38) MEN1KMT2AKDM4EPARGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1649283-B1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LTD (GB) 2014-06-18 EP disclosed
US-8334387-B2 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2012-12-18 US disclosed
US-8334387-B2 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2012-12-18 US disclosed
US-8334387-B2 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2012-12-18 US disclosed
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2011-01-20 US disclosed
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2011-01-20 US disclosed
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2011-01-20 US disclosed
US-7829714-B2 Method for measuring aromatase activity GE HEALTHCARE LIMITED (GB) 2010-11-09 US disclosed
US-20100184098-A1 METHODS FOR MEASURING ENZYME ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2010-07-22 US disclosed
US-20100184098-A1 METHODS FOR MEASURING ENZYME ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2010-07-22 US disclosed
US-7727739-B2 Methods for measuring enzyme activity GE HEALTHCARE UK LIMITED (GB) 2010-06-01 US disclosed
US-7727739-B2 Methods for measuring enzyme activity GE HEALTHCARE UK LIMITED (GB) 2010-06-01 US disclosed
US-7335771-B2 Quinacridone derivatives as labelling reagents for fluorescence detection of biological materials GE HEALTHCARE UK LIMITED (GB) 2008-02-26 US disclosed
US-20070184429-A1 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2007-08-09 US disclosed
US-20070184429-A1 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2007-08-09 US disclosed
US-20070184429-A1 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2007-08-09 US disclosed
EP-1649283-A2 METHOD FOR MEASURING AROMATASE ACTIVITY GE Healthcare UK Limited (GB) 2006-04-26 EP disclosed
WO-2005012901-A2 METHOD FOR MEASURING AROMATASE ACTIVITY AMERSHAM BIOSCIENCES UK LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY CYP19A1, CYP17A1, CYP21A2 MEN1 1057/4885KMT2A 515/4885KDM4E 751/4885
US-20070184429-A1 Method for measuring aromatase activity CYP19A1, CYP17A1, CYP21A2 MEN1 1057/4885KMT2A 515/4885KDM4E 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.